Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.
about
International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease statesBombesin-related peptides and their receptors: recent advances in their role in physiology and disease statesLoss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapseAEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.Targeted chemotherapy using a cytotoxic somatostatin conjugate to inhibit tumor growth and metastasis in nude mice.Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer.Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cellsSynthesis and biological evaluation of a novel pentagastrin-toxin conjugate designed for a targeted prodrug mono-therapy of cancer.Expression of neuropeptide hormone receptors in human adrenal tumors and cell lines: antiproliferative effects of peptide analogues.Vasoactive intestinal peptide-camptothecin conjugates inhibit the proliferation of breast cancer cells.Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology.Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells--analysis of the molecular mechanisms of its antiproliferative action.Bombesin marine toxin conjugates inhibit the growth of lung cancer cells.
P2860
Q24643524-F4278115-B0C9-409F-B292-C0CC06EAD8F8Q24645097-610ED58B-1B6B-4491-85B4-59CFBA6E15D8Q28540624-8A32545E-734D-48FD-816D-D219059014CAQ34274245-D741FDCC-F02C-4DE2-973C-7A0ECBD80C9AQ35180952-1EE09291-7179-4B84-81C7-5F579CE77F80Q35650181-61A22F05-2A3D-4224-AD43-052D5D960CF2Q36948906-D9438775-FD3B-456A-896F-07F27E365B7CQ37083440-8C7EA3E5-558B-4A6B-B8A7-F38108560EF7Q37323454-4739F202-EB1B-43EE-8944-6A42D667A9F8Q37342513-C62D4C63-8765-4015-807A-811E3127E2D2Q37579225-6F040267-D6FB-4960-AE40-1D8BF08A95FAQ38007373-7C7924AF-6C92-4662-A4EB-74D0E6DAC891Q39631743-DC64B01D-2419-4751-9FDB-75BE6ED30D64Q40003185-2CD1C104-C66C-4894-B1C5-46C67F6A0567
P2860
Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Therapy of ovarian cancers wit ...... ormone and their combinations.
@ast
Therapy of ovarian cancers wit ...... ormone and their combinations.
@en
Therapy of ovarian cancers wit ...... ormone and their combinations.
@nl
type
label
Therapy of ovarian cancers wit ...... ormone and their combinations.
@ast
Therapy of ovarian cancers wit ...... ormone and their combinations.
@en
Therapy of ovarian cancers wit ...... ormone and their combinations.
@nl
prefLabel
Therapy of ovarian cancers wit ...... ormone and their combinations.
@ast
Therapy of ovarian cancers wit ...... ormone and their combinations.
@en
Therapy of ovarian cancers wit ...... ormone and their combinations.
@nl
P2093
P2860
P50
P356
P1476
Therapy of ovarian cancers wit ...... hormone and their combinations
@en
P2093
Benjamin Baker
Elmar Heinrich
Florian Hohla
Frank Koester
Gunhild Keller
Stefan Buchholz
P2860
P304
10403-10407
P356
10.1073/PNAS.0602971103
P407
P577
2006-06-26T00:00:00Z